乙肝病毒(HBV)是有缺口的双链DNA病毒,侵入人体肝细胞后形成共价闭合环状DNA(cccDNA)持续复制,并在逆转录过程中随机整合入宿主基因组。慢性乙型肝炎感染者平均每个细胞中含有33个cccDNA拷贝,半衰期长达35~57 d,很难从体内彻底清除。利用锁核酸抑制HBV转录,是乙肝治疗的新策略。此外,利用基因组编辑技术靶向切割HBV基因组,有望从源头治愈乙型肝炎。基于锁核酸与双链DNA形成三股螺旋的能力、抵御核酸酶及聚合酶的稳定性以及对单碱基错配的敏感性,本研究以靶向切割乙型肝炎病毒为例,设计构建锁核酸修饰的寡核苷酸作为DNA结合域,有效增强对靶基因的特异性识别;同时利用FokⅠ核酸酶分子量小、二聚化时才具有酶活等特点,设计构建FokⅠ切割域二聚体重组蛋白作为DNA切割域;进而通过双功能交联剂GMBS,建立了5′端氨基(-NH2)修饰的锁核酸与N端巯基(-SH)修饰的FokⅠ核酸酶定向化学偶联的方法,并在体外验证了新型工具对HBV基因的靶向切割。该方法为此后在体内进行高特异性、无整合风险的抗病毒基因治疗提供了全新的技术思路。
Hepatitis B virus (HBV) is a dented double-stranded DNA virus. After infecting human hepatic cells, it forms cccDNA that replicates persistently and integrates randomly into the host’s genome during the process of reserve transcription. On average, in each cell with chronic HBV infection, there are about 33 copies of cccDNA with a half of 35-57 days, which can be difficult to eradicate. A new strategy is to inhibit HBV transcription by using locked nucleic acid (LNA). Besides, cleaving HBV genome by targeted genome editing technologies could potentially cure patients. In this study, we explored new genome editing tools for HBV treatment. Based on LNA’s ability to form triple helix by binding to duplex DNA, its stability towards nuclease and polymerase, and its sensitivity to single base mismatches, we designed LNA-modified oligonucleotides as DNA binding domain to effectively increase the specificity of target gene recognition. Meanwhile, by utilizing the small molecular weight and dimerization dependent activity of nuclease FokⅠ, we used FokⅠrecombinant dimer protein as DNA cleavage domain. Here, we established a method by chemical coupling of LNA-oligonucleotide with FokⅠcleavage domain, and also validated the targeted cleavage of HBV genes with our new tools in vitro. These results provide new possibilities for future in vivo anti-virus gene therapy with high specificity and no integration risk.
[1] Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol , 2006, 45(4): 529-538.
[2] Jia F, Zhang YZ, Liu CM. Stable inhibition of hepatitis B virus expression and replication in HepG2.2.15 cells by RNA interference based on retrovirus delivery. J Biotechnol , 2007, 128(1): 32-40.
[3] Weber ND, Stone D, Sedlak RH, De Silva FHS, Roychoudhury P, Schiffer JT, Aubert M, Jerome KR. AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication. PLoS One , 2014, 9(5): e97579.
[4] Chen JL, Zhang W, Lin JY, Wang F, Wu M, Chen CC, Zheng Y, Peng XH, Li JH, Yuan ZH. An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases. Mol Ther, 2014, 22(2): 303-311.
[5] Karimova M, Beschorner N, Dammermann W, Chemnitz J, Indenbirken D, Bockmann JH, Grundhoff A, Lüth S, Buchholz F, zur Wiesch JS, Hauber J. CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X. Sci Rep , 2015, 5: 13734.
[6] Liu J, Gaj T, Wallen MC, Barbas CF. Improved cell-penetrating zinc-finger nuclease proteins for precision genome engineering. Mol Ther Nucleic Acids , 2015, 4: e232.
[7] Wade M. High-Throughput silencing using the CRISPR- Cas9 system: A review of the benefits and challenges. J Biomol Screen , 2015, 20(8): 1027-1039.
[8] Koshkin AA, Singh SK, Nielsen P, Rajwanshi VK, Kumar R, Meldgaard M, Olsen CE, Wengel J. LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron , 1998, 54(14): 3607-3630.
[9] Latorra D, Campbell K, Wolter A, Michael Hurley J. Enhanced allele-specific PCR discrimination in SNP genotyping using 3′ locked nucleic acid (LNA) primers. Hum Mutat , 2003, 22(1): 79-85.
[10] Fluiter K, Ten Asbroek ALMA, de Wissel MB, Jakobs ME, Wissenbach M, Olsson H, Olsen O, Oerum H, Baas F. In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides. Nucl Acids Res , 2003, 31(3): 953-962.
[11] Brunet E, Alberti P, Perrouault L, Babu R, Wengel J, Giovannangeli C. Exploring cellular activity of locked nucleic acid-modified triplex-forming oligonucleotides and defining its molecular basis. J Biol Chem , 2005, 280(20): 20076-20085.
[12] Sun Z, Xiang WQ, Guo YJ, Chen Z, Liu W, Lu DR. Inhibition of hepatitis B virus (HBV) by LNA-mediated nuclear interference with HBV DNA transcription. Biochem Biophys Res Commun , 2011, 409(3): 430-435.
[13] Wah DA, Bitinaite J, Schildkraut I, Aggarwal AK. Structure of Fok I has implications for DNA cleavage. Proc Natl Acad Sci USA , 1998, 95(18): 10564-10569.
[14] Li T, Huang S, Jiang WZ, Wright D, Spalding MH, Weeks DP, Yang B. TAL nucleases (TALNs): Hybrid proteins composed of TAL effectors and Fok I DNA-cleavage domain. Nucleic Acids Res , 2011, 39(1): 359-372.
[15] Miller JC, Holmes MC, Wang JB, Guschin DY, Lee YL, Rupniewski I, Beausejour CM, Waite AJ, Wang NS, Kim KA, Gregory PD, Pabo CO, Rebar EJ. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol , 2007, 25(7): 778-785.
[16] Minczuk M, Papworth MA, Miller JC, Murphy MP, Klug A. Development of a single-chain, quasi-dimeric zinc- finger nuclease for the selective degradation of mutated human mitochondrial DNA. Nucl Acids Res , 2008, 36(12): 3926-3938.
[17] Henke E, Perk J, Vider J, de Candia P, Chin Y, Solit DB, Ponomarev V, Cartegni L, Manova K, Rosen N, Benezra R. Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo . Nat Biotechnol , 2008, 26(1): 91-100.
[18] Lu K, Duan QP, Ma L, Zhao DX. Chemical strategies for t
